ClinicalTrials.gg
CompletedNCT06482892Updated Sep 30, 2026

TP03HN106 in Patients With Critical Limb Ischemia

A Phase 2 interventional study of TP03HN106 in Critical Limb Ischemia, sponsored by Talengen Institute of Life Sciences, Shenzhen, P.R. China.. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Talengen Institute of Life Sciences, Shenzhen, P.R. China. · Phase 2, Interventional, and Treatment

How we know

Updated Sep 30, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Chronic Limb-Threatening Ischemia with a site in China — 7 open to participants now, 7 under way, none of them phase 3. Chronic Limb-Threatening Ischemia · China.

Enrollment
14th of 15
15 · median 120
Started
2024
with 2 others
Phase 2
2 of 23
none open now
Registered
18th of 23
by date

Among the 23 studies in Chronic Limb-Threatening Ischemia with a site in China, this one is the 14th largest by enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2024, is one of 2 in phase 2, and was the 18th registered.

Chronic Limb-Threatening Ischemia

359 studies on the registry are indexed under Chronic Limb-Threatening Ischemia; 73 are open to participants now.

Browse Chronic Limb-Threatening Ischemia studies →

Open to participants now

7 of the 23 studies in Chronic Limb-Threatening Ischemia with a site in China are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 51 Chronic Limb-Threatening Ischemia studies recruiting now, 35 (69%) set no upper age limit and 2 (4%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Chronic Limb-Threatening Ischemia with a site in China, or all of them as a file.
02

Study summary

Critical limb ischemia (CLI) is the most severe ischemic stage in peripheral arterial disease (PAD) of the lower limbs, characterized by decreased walking ability, resting pain (lasting for more than 2 weeks), ulcers, and gangrene, which seriously affect the quality of life of patients. Some patients may even face amputation or death. Thrombosis is an important pathological feature of CLI. TP03HN106 can promote thrombolysis, thus having a therapeutic effect on CLI.

03

Conditions studied

  • Critical Limb Ischemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. When signing the form, the age should be ≥ 18 years old, regardless of gender;
  2. Clinically diagnosed as a patient with Critical limb ischemia, with a Rutherford score of 4-6.
  3. Patients who are unable to undergo interventional surgical treatment, or whose previous interventional surgical treatment is ineffective, or who are unwilling to undergo any intervention or surgical treatment, and can only receive conventional antiplatelet and vasodilator drugs (before baseline, antiplatelet and vasodilator drugs must be used for at least 1 week);
  4. During the screening period, lower limb artery color ultrasound or lower limb computed tomography angiography (CTA) showed severe stenosis or occlusion of one or more of the common iliac artery, external iliac artery, common femoral artery, superficial femoral artery, popliteal artery, anterior tibial artery, posterior tibial artery, and fibular artery;
  5. During the screening period, if there are severe symptoms of lower limb ischemia, meeting any of the following symptoms is sufficient: There is limb rest pain caused by lower limb ischemia, with a disease duration of ≥ 2 weeks, and a VAS score of ≥ 40mm and \< 100mm before the first administration; There are limb tissue ulcers caused by lower limb ischemia, with a disease duration of ≥ 2 weeks and limb ulcers (4cm2 ≤ maximum single ulcer area ≤ 25cm2);
  6. All subjects with fertility or their spouses must take effective measures within 3 months after signing the informed consent form until the completion of the trial;
  7. The subjects voluntarily give informed consent and sign an informed consent form (if the subjects and/or their guardians lack reading ability and cannot understand the content of the informed consent, they need to sign together with a fair witness), fully understand the methods and procedures of the experiment, and be able to provide biological samples for testing related indicators in accordance with the experiment requirements.

Exclusion criteria

Exclusion Criteria:

  1. Subjects who are known to be allergic to the drug, its , or other human blood products;
  2. Patients with limb gangrene greater than 4 cm2;
  3. Patients currently suffering from malignant tumor diseases (including those who have previously had malignant tumors but have not been cured);
  4. Screening period for patients with liver and kidney failure:
  5. Patients who require hemodialysis;
  6. Those who have experienced cerebral infarction or cerebral hemorrhage within 3 months prior to signing the form;
  7. During the screening period, subjects with mental illness, obvious mental disorders or epilepsy, including other individuals with no behavioral or cognitive abilities;
  8. Hypertensive patients (SBP ≥ 160mmHg and/or DBP ≥ 100mmHg) who cannot be controlled after standardized treatment in the screening period;
  9. Individuals who have received fresh plasma, cold precipitates, or blood products containing TP03HN106 components within one month prior to signing the informed consent form;
  10. Those who have participated in clinical trials of other drugs or medical devices within one month before signing the informed consent form;
  11. Those who have undergone or plan to undergo surgery during the trial period within one month prior to signing the informed consent form;
  12. Alcoholism and/or psychoactive substances, drug abusers and dependents (alcoholism standard: the weekly alcohol intake is more than 21 units (male) and 14 units (female) (1 unit=360 mL beer; or 150 mL wine; or 45 mL white spirit);
  13. Miscarriage or termination of pregnancy less than 3 months prior to signing the informed consent form, pregnant women and lactating women (currently breastfeeding or not artificially breastfeeding but less than 6 months after delivery);
  14. Poor compliance or any other situation that the researcher deems unsuitable for inclusion.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Treatment group

    Drug: TP03HN106

Interventions

  • DrugTP03HN106

    During the dose escalation phase, subjects will undergo a dose escalation trial of intravenous injection of TP03HN106 for 5 consecutive days to evaluate the safety and tolerance of the subjects to the injection dose of TP03HN106. The preset initial dose for this experiment is 10U/kg, with gradient doses of 20, 30, 40, and 50U/kg. Observe the subjects receiving the investigational drug for any adverse events (AEs) after daily intravenous injection. During the maintenance treatment phase, the subjects will undergo two consecutive treatment courses at the final dose during the dose escalation phase. During each treatment course, subjects will complete the collection of efficacy and safety data for 14 consecutive days of medication (administered every 2 days) and 14 days of discontinuation to evaluate the efficacy and safety of TP03HN106 for subjects with critical limb ischemia.

06

What researchers measure

Primary outcomes

  1. Overall clinical treatment efficacy rate

    The VAS score or ulcer area decreases by ≥ 50% compared to baseline when administering day 62, it is considered a clinically effective case. The overall clinical efficacy of patient treatment is calculated according to the following formula: Overall clinical treatment effectiveness rate=(number of clinically effective cases/total cases) × 100% When the calculated overall clinical success rate is ≥ 70%, the entire clinical trial is considered successful.

    Time frame: Day 62

Secondary outcomes

  1. Ankle brachial index, ABI

    Changes in ABI of subjects (applicable to patients with ulcers) compared to baseline during administration of day 6, day 21, day 34, day 49, and day 62 ABI:The ratio of ankle artery systolic pressure to ipsilateral brachial artery systolic pressure

    Time frame: Baseline, day 6, day 21, day 34, day 49, and day 62

  2. TcPO2

    Changes in TcPO2 of subjects (applicable to patients with ulcers) compared to baseline during administration of day 6, day 21, day 34, day 49, and day 62 TcPO2: transcutaneous oxygen partial pressure

    Time frame: Baseline, day 6, day 21, day 34, day 49, and day 62

  3. TBI

    Changes in TBI of subjects compared to baseline during administration of day 6, day 21, day 34, day 49, and day 62 TBI: The ratio of toe artery systolic pressure to ipsilateral brachial artery systolic pressure

    Time frame: Baseline, day 6, day 21, day 34, day 49, and day 62

  4. Overall clinical treatment efficacy rate

    The VAS score or ulcer area decreases by ≥ 50% compared to baseline when administering day 6, day 14, day 21, day 34, day 49, it is considered a clinically effective case. The overall clinical efficacy of patient treatment is calculated according to the following formula: Overall clinical treatment effectiveness rate=(number of clinically effective cases/total cases) × 100% When the calculated overall clinical success rate is ≥ 70%, the entire clinical trial is considered successful.

    Time frame: Day 6, day 14, day 21, day 34, day 49

  5. Rutherford grading

    Changes in Rutherford grading of subjects compared to baseline during administration of day 6, day 21, day 34, day 49, and day 62

    Time frame: Baseline, day 6, day 21, day 34, day 49, and day 62

Other outcomes

  1. Coagulation function indicators

    Changes in coagulation function of subjects compared to baseline during administration of day 6, day 21, day 34, day 49, and day 62

    Time frame: Baseline, day 6, day 21, day 34, day 49, and day 62

  2. Fibrinogen degradation products (FDP)

    Changes in FDP of subjects compared to baseline during administration of day 6, day 21, day 34, day 49, and day 62

    Time frame: Baseline, day 6, day 21, day 34, day 49, and day 62

  3. Thrombosis 4 items

    Changes in thrombosis 4 items of subjects compared to baseline during administration of day 6, day 21, day 34, day 49, and day 62

    Time frame: Baseline, day 6, day 21, day 34, day 49, and day 62

  4. Computed tomography perfusion (CTP)

    Changes in blood volume of subjects compared to baseline during administration of day 34 and day 62

    Time frame: Baseline,day 34, day 62

  5. Infrared thermal imaging

    Measure the temperature of the feet and lower leg

    Time frame: Baseline,day 34, day 62

  6. Computed tomography perfusion (CTP)

    Changes in blood flow of subjects compared to baseline during administration of day 34 and day 62

    Time frame: Baseline,day 34, day 62

07

Study locations

1 site
  • The First Affiliated Hospital of Soochow University
    Suzhou, Jiangsu 215000, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jul 2024 to primary completion in Mar 2026, 19 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: primary completion Sep 2025 → Mar 2026 and completion Dec 2025 → May 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2024
First posted
Jul 1, 2024
StartActual
Jul 18, 2024
Primary completionActual
Mar 10, 2026was Sep 2025
CompletionActual
May 30, 2026was Dec 2025
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Sep 30, 2026
Primary completion
Sep 30, 2025→Mar 10, 2026 (actual)
Sep 30, 2026
Study completion
Dec 30, 2025→May 30, 2026 (actual)
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Recruiting→Completed
    Primary completion Sep 30, 2025→Mar 10, 2026 (now actual)
    Study completion Dec 30, 2025→May 30, 2026 (now actual)
    + 4 other changes: verification date, contact details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06482892
Lead sponsor
Talengen Institute of Life Sciences, Shenzhen, P.R. China.
Responsible party
Sponsor
First posted
Jul 1, 2024
Start date
Jul 18, 2024
Primary completion
Mar 10, 2026
Completion
May 30, 2026
Last update
Sep 30, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion